Original Publication Date: >1 May, 2015
Publication / Source: CNS Oncology
Authors: Roy E Strowd III, Inas A Abuali & Stuart A Grossman
Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL.